Brief: Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine Program
08/10/2025 13:25
Oct 8 (Reuters) - Nasus Pharma Ltd NSRX.A: NASUS PHARMA ANNOUNCES EXPANDED AGREEMENT TO SUPPORT DEVELOPMENT AND COMMERCIALIZATION OF NS002 INTRANASAL EPINEPHRINE PROGRAM Source text: ID:nGNX16VltF Further company coverage: NSRX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nasus Pharma
See all newsBrief: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'grady As Chief Executive Officer To Lead Strategic Growth
Brief: Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold
Brief: Nasus Pharma Announces Closing Of $15.0 Million Private Placement
Brief: Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial Officer
Brief: Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed